Download PDF

1. Company Snapshot

1.a. Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.


Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute.The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital.The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Show Full description

1.b. Last Insights on INO

Inovio Pharmaceuticals' recent performance was negatively impacted by a manufacturing issue concerning the single-use array component of the CELLECTRA device, which was resolved in the fourth quarter of 2024. The company also faced a delay in the device design verification (DV) testing required for the Biologics License Application (BLA) submission for INO-3107, a potential treatment for recurrent respiratory papillomatosis (RRP). Additionally, the company's proof-of-concept Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs) was ongoing, but no significant updates were provided in the recent earnings release.

1.c. Company Highlights

2. Inovio's Q4 2025: A Surge in Revenue and a Strategic Push for INO-3107

In the fourth quarter of 2025, Inovio reported a staggering 526.8% increase in revenue, driven by the launch of its BLA for INO-3107 and the anticipation of accelerated approval. Earnings per share rose to $0.31, surpassing analysts' estimate of –$0.37, as the company reported a net loss of $4.2 million on $12.5 million in revenue. Gross margin climbed to 45%, up from 38% in the prior year, reflecting improved cost management and higher pricing power. Cash and short‑term investments stood at $58.5 million, extending the runway into Q4 2026. (Dr. Shea, 2025 Q4 Call)

Publication Date: Apr -14

📋 Highlights
  • BLA Acceptance with Eligibility Concerns:: FDA accepted INO-3107 BLA for RRP under accelerated approval but raised eligibility concerns, with Inovio asserting it meets criteria via unmet need and 50-100% surgery reduction in trials.
  • Phase I/II Trial Efficacy:: 50-100% reduction in surgeries for RRP patients, with most achieving 0 surgeries during dosing window, demonstrating strong therapeutic benefit over existing treatments.
  • Extended Cash Runway:: $58.5M in cash/cash equivalents (Q4 2025) and cash burn of ~$22M for Q1 2026, extending runway to Q4 2026.
  • Commercial Readiness:: Market research validates INO-3107 as preferred treatment due to efficacy, tolerability, and simple regimen; commercial partners and logistics partners selected for rapid launch.
  • INSIGhT Trial Focus:: Trial targeting RRP patients with unmethylated disease (poorer prognosis) to further validate INO-3107’s efficacy in high-need populations.

BLA Acceptance and Accelerated Approval Strategy

The FDA accepted Inovio’s Biologics License Application for INO-3107 under the accelerated approval pathway, a milestone that positions the company to potentially bring the therapy to market within 12 months. Dr. Jacqui Shea emphasized that INO-3107 addresses an unmet medical need for adults with recurrent respiratory papillomatosis (RRP), offering a 50–100% reduction in surgeries. The FDA’s only concern—eligibility for accelerated approval—has been mitigated by the company’s robust clinical data and a compelling assessment aid that reiterates the therapy’s meaningful benefit over existing options.

Phase I/II Clinical Success and Safety Profile

Phase I/II trials demonstrated that the majority of patients achieved a 50–100% reduction in surgical interventions, with most requiring zero surgeries during the dosing window. Dr. Michael Sumner highlighted the improved safety profile relative to current treatments, noting that adverse events were mild and transient. This efficacy data underpins the company’s accelerated approval rationale and builds confidence among payers and clinicians seeking less invasive management for RRP.

Commercial Momentum and Market Readiness

Chief Commercial Officer Steve Egge outlined a pre‑launch plan that includes strategic partner selection, third‑party logistics, and a streamlined treatment regimen. Market research confirms that patients and physicians favor INO-3107’s profile, with potential to become the preferred treatment due to its efficacy and tolerability. The company has already secured preliminary agreements with commercial partners and is poised to launch quickly upon FDA approval, leveraging lessons from the PAPZIMEOS rollout and competitor experiences in the rare disease space.

Valuation Snapshot and Future Outlook

Despite the promising revenue trajectory, Inovio trades at a distressed valuation: P/E of –6.02, P/B of 21.21, and EV/EBITDA of –0.29, reflecting the company’s current loss position. The P/S ratio sits at 893.94, underscoring high sales expectations relative to earnings. Net Debt/EBITDA stands at 0.43, indicating modest leverage. Free Cash Flow Yield is –152.22% and ROIC is –259.45%, highlighting negative cash generation. Investors should weigh the upside potential of accelerated approval against the company’s cash burn of $22 million in Q1 2026 and the need for additional capital to sustain growth.

3. NewsRoom

Card image cap

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO

Apr -07

Source: globenewswire.com

Card image cap

INO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

Apr -07

Source: prnewswire.com

Card image cap

DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Apr -07

Source: globenewswire.com

Card image cap

INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026

Apr -07

Source: businesswire.com

Card image cap

INO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law Firm

Apr -07

Source: prnewswire.com

Card image cap

INOVIO DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - INO

Apr -06

Source: newsfilecorp.com

Card image cap

Deadline Soon: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Apr -06

Source: businesswire.com

Card image cap

Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Apr -06

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.37%)

6. Segments

DNA Medicines

Expected Growth: 11.37%

Inovio Pharmaceuticals' DNA Medicines segment growth of 11.37% is driven by increasing demand for its proprietary electroporation-based DNA delivery technology, expansion into new therapeutic areas such as infectious diseases and cancer, and strategic partnerships with biotech and pharma companies.

7. Detailed Products

Electroporation Delivery Devices

Inovio's electroporation delivery devices are designed to enhance the potency of DNA-based vaccines and therapies by using controlled electrical pulses to create temporary pores in the cell membrane, allowing for more efficient uptake of the DNA.

DNA-Based Vaccines

Inovio's DNA-based vaccines use a proprietary plasmid design to stimulate an immune response, providing protection against various diseases and infections.

Immuno-Oncology Therapies

Inovio's immuno-oncology therapies are designed to stimulate the immune system to attack and destroy cancer cells, providing a potential treatment for various types of cancer.

SynCon® Vaccines

Inovio's SynCon vaccines are designed to provide broad protection against multiple strains of a virus, providing a potential solution for rapidly mutating viruses.

CELLECTRA® 3PSP

Inovio's CELLECTRA 3PSP is a proprietary electroporation device designed to enhance the potency of DNA-based vaccines and therapies.

8. Inovio Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Inovio Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and vaccines for infectious diseases.

Bargaining Power Of Customers

Inovio Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.

Bargaining Power Of Suppliers

Inovio Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Inovio Pharmaceuticals, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the ease of entry for new companies.

Intensity Of Rivalry

Inovio Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 20.47%
Debt Cost 4.05%
Equity Weight 79.53%
Equity Cost 9.76%
WACC 8.59%
Leverage 25.74%

11. Quality Control: Inovio Pharmaceuticals, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Revance Therapeutics

A-Score: 5.1/10

Value: 8.6

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
TRACON Pharmaceuticals

A-Score: 4.9/10

Value: 10.0

Growth: 7.0

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Matinas BioPharma

A-Score: 4.1/10

Value: 8.4

Growth: 4.2

Quality: 3.4

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Vericel

A-Score: 3.4/10

Value: 0.7

Growth: 7.9

Quality: 5.9

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Unicycive Therapeutics

A-Score: 3.4/10

Value: 6.7

Growth: 4.8

Quality: 3.8

Yield: 0.0

Momentum: 3.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Inovio Pharmaceuticals

A-Score: 2.0/10

Value: 6.7

Growth: 0.3

Quality: 3.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.16$

Current Price

1.16$

Potential

-0.00%

Expected Cash-Flows